Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025.
Quiver AI Summary
Immutep Limited has released promising initial safety data for IMP761, the world's first LAG-3 agonist, from its first-in-human Phase I clinical trial, which has shown no treatment-related adverse events in the initial cohorts of healthy participants. The study, designed to evaluate the safety and immunosuppressive efficacy of IMP761, aims to enhance the immune system's regulation by silencing dysregulated T cells associated with autoimmune diseases. Conducted at the Centre for Human Drug Research in the Netherlands, the trial will also assess pharmacokinetic and pharmacodynamic relationships with additional data expected in the first half of 2025. IMP761 targets autoimmune conditions such as rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, and has demonstrated efficacy in preclinical studies by significantly reducing inflammatory cytokines.
Potential Positives
- Favourable initial safety data indicating no treatment-related adverse events in the first three cohorts of the Phase I study for IMP761.
- IMP761 is the world’s first LAG-3 agonist antibody, demonstrating significant potential to treat a range of autoimmune diseases by restoring immune balance.
- Encouraging preclinical data showing IMP761's effectiveness in decreasing inflammatory cytokines and T cell responses, supporting its promising therapeutic profile.
- Upcoming assessment of additional safety data and pharmacokinetic/pharmacodynamic relationships expected in the first half of CY2025, indicating ongoing commitment to thorough evaluation and transparency.
Potential Negatives
- The press release indicates that while there have been no treatment-related adverse events reported to date, the phase I trial is still ongoing, which inherently carries the risk that potential issues may arise as the study progresses.
- Additional safety data and assessments of pharmacokinetic/pharmacodynamic relationships are not expected until the first half of CY2025, leaving a lengthy period of uncertainty regarding the overall safety and efficacy of IMP761.
- The necessity of conducting further clinical trials to establish the full safety and therapeutic effect of IMP761 may imply that the product is not yet ready for market, potentially delaying revenue generation for the company.
FAQ
What is IMP761?
IMP761 is the world's first LAG-3 agonist antibody designed to restore immune balance and treat autoimmune diseases.
What are the initial safety results for IMP761?
Initial results show no treatment-related adverse events in a Phase I trial of IMP761 with healthy participants.
When will additional safety data for IMP761 be available?
Additional safety data and pharmacokinetic/pharmacodynamic assessments for IMP761 are expected in the first half of CY2025.
How does IMP761 work in autoimmune diseases?
IMP761 enhances the "brake" function of LAG-3 on T cells, helping to silence dysregulated memory T cells.
What diseases might IMP761 potentially treat?
IMP761 is being developed to address various autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMMP Hedge Fund Activity
We have seen 12 institutional investors add shares of $IMMP stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORACLE INVESTMENT MANAGEMENT INC removed 564,879 shares (-100.0%) from their portfolio in Q2 2024
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 135,614 shares (-54.7%) from their portfolio in Q3 2024
- OLD MISSION CAPITAL LLC removed 113,037 shares (-100.0%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 90,224 shares (-85.7%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 77,116 shares (-79.7%) from their portfolio in Q3 2024
- BLACKROCK, INC. added 69,060 shares (+8.2%) to their portfolio in Q3 2024
- XY CAPITAL LTD added 56,344 shares (+108.3%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to date
Additional safety data and assessment of PK/PD relationships to follow in first half of CY2025
IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases
SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) --
Immutep Limited
(ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. Through the first three of five single ascending dose cohorts in healthy participants, there have been no treatment related adverse events.
Dr. Frédéric Triebel, CSO of Immutep, said: “We are very encouraged by the safety data generated to date for IMP761, the world’s first LAG-3 agonist antibody, in this Phase I setting. Derisking this promising asset in this proof-of-concept study in healthy subjects assessing its safety and immunosuppressive efficacy on an antigen-specific T-cell mediated intra-dermal reaction is an important step for this exciting program in autoimmune diseases. Given that IMP761 is potentially addressing the root cause of many different autoimmune diseases, we are eager to see this study generating more data.”
The trial in up to 49 participants is being conducted by the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. In addition to the safety analysis, CHDR is implementing its keyhole limpet haemocyanin (KLH) challenge model to evaluate IMP761’s pharmacological activity. Additional safety data and assessment of pharmacokinetic/pharmacodynamic (PK/PD) relationships to follow in the first half of CY2025.
The LAG-3 (lymphocyte-activation gene-3) immune checkpoint has been identified as a promising target for an agonist antibody to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among potentially many other autoimmune diseases.
1,2,3
This first-in-class agonist LAG-3 antibody is designed to restore balance to the immune system by enhancing the “brake” function of LAG-3 to silence dysregulated self-antigen-specific memory T cells that cause many autoimmune diseases. In preclinical studies, IMP761 has led to a large decrease in inflammatory cytokines and demonstrated its effectiveness in suppressing antigen-specific T cell–mediated immune responses.
4,5
For more information on the trial, please visit clinicaltrials.gov (NCT06637865).
About IMP761
IMP761, a first-in-class immunosuppressive lymphocyte-activation gene-3 (LAG-3) agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the immune system. As published in the
Journal of Immunology
, encouraging pre-clinical
in vivo
and
in vitro
studies show IMP761 inhibits peptide-induced T cell proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction. Additional preclinical data in oligoarticular juvenile idiopathic arthritis (o-JIA) published in
Pediatric Research
details how IMP761 led to a decrease in a broad spectrum of effector cytokines in just 48 hours. This study also showed children with o-JIA have a skewed LAG-3 metabolism and suggested they can benefit from agonistic LAG-3 activity.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit
www.immutep.com
.
1. Pedersen, J.M., Hansen, A.S., Skejø, C. et al. Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis. Arthritis Res Ther 25, 97 (2023). https://doi.org/10.1186/s13075-023-03073-z
2. Jones BE, Maerz MD et al. Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. J Immunol. 2022 Feb 1;208(3):594-602. doi: 10.4049/jimmunol.2100850. Epub 2022 Jan 12. PMID: 35022272; PMCID: PMC8820445.
3. Zhou X, Gu Y et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases. Inflamm Res. 2023 Jun;72(6):1215-1235. doi: 10.1007/s00011-023-01742-y. Epub 2023 Jun 14. PMID: 37314518.
4. Mathieu Angin, Chrystelle Brignone, Frédéric Triebel; A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases. J Immunol 15 February 2020; 204 (4): 810–818. https://doi.org/10.4049/jimmunol.1900823
5. Sag, E., Demir, S., Aspari, M. et al. Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes. Pediatr Res 90, 744–751 (2021). https://doi.org/10.1038/s41390-021-01588-2
Australian Investors/Media:
Catherine Strong, Sodali & Co
+61 (0)406 759 268;
catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000;
chris.basta@immutep.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
